IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?

Rizvi, 2013, Pathogenesis, diagnosis, and management of cholangiocarcinoma, Gastroenterology, 145, 1215, 10.1053/j.gastro.2013.10.013 Waseem, 2017, Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes, Ann. Hepatol., 16, 133, 10.5604/16652681.1226927 Forner, 2019, Clinical presentation, diagnosis and staging of cholangiocarcinoma, Liver Int., 39, 98, 10.1111/liv.14086 Rizzo, 2021, PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer, Cancers Basel, 13, 558, 10.3390/cancers13030558 Razumilava, 2014, Cholangiocarcinoma, Lancet, 383, 2168, 10.1016/S0140-6736(13)61903-0 Saha, 2016, Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise, Oncologist, 21, 594, 10.1634/theoncologist.2015-0446 Bridgewater, 2016, Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling, Am. Soc. Clin. Oncol. Educ. Book, 35, e194, 10.1200/EDBK_160831 Schweitzer, 2017, Risk estimation for biliary tract cancer: development and validation of a prognostic score, Liver Int., 37, 1852, 10.1111/liv.13517 Banales, 2016, Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European network for the study of cholangiocarcinoma (ENS-CCA), Nat. Rev. Gastroenterol. Hepatol., 13, 261, 10.1038/nrgastro.2016.51 Matsukuma, 2019, Essential updates to the surgical treatment of biliary tract cancer, Ann. Gastroenterol. Surg., 3, 378, 10.1002/ags3.12266 DeOliveira, 2007, Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution, Ann. Surg., 245, 755, 10.1097/01.sla.0000251366.62632.d3 Rizzo, 2021, Adjuvant systemic treatment in resected biliary tract cancer: state of the art, controversies, and future directions, Cancer Treat. Res. Commun., 27 Kasumova, 2017, Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy, Ann. Surg., 266, 625, 10.1097/SLA.0000000000002385 Rizzo, 2020, BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care, Expert Rev. Gastroenterol. Hepatol., 18, 1, 10.1080/17474124.2021.1864325 Horgan, 2012, Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis, J. Clin. Oncol., 30, 1934, 10.1200/JCO.2011.40.5381 Primrose, 2019, Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study, Lancet Oncol., 20, 663, 10.1016/S1470-2045(18)30915-X Lamarca, 2020, Current standards and future perspectives in adjuvant treatment for biliary tract cancers, Cancer Treat. Rev., 84, 10.1016/j.ctrv.2019.101936 Currie, 2017, Decision making: intra-arterial therapies for cholangiocarcinoma-TACE and TARE, Semin. Intervent. Radiol., 34, 92, 10.1055/s-0037-1602591 Sommer, 2016, Locoregional therapies of cholangiocarcinoma, Visc. Med., 32, 414, 10.1159/000453010 Rizzo, 2021, Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer, Expert Rev. Gastroenterol. Hepatol., 19, 1 Valle, 2010, ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer, N. Engl. J. Med., 362, 1273, 10.1056/NEJMoa0908721 Valle, 2014, Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials, Ann. Oncol., 25, 391, 10.1093/annonc/mdt540 Mizrahi, 2020, New treatment options for advanced biliary tract cancer, Curr. Treat. Options Oncol., 21, 63, 10.1007/s11864-020-00767-3 Kelley, 2020, Systemic therapies for intrahepatic cholangiocarcinoma, J. Hepatol., 72, 353, 10.1016/j.jhep.2019.10.009 Shroff, 2019, Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial, JAMA Oncol., 5, 824, 10.1001/jamaoncol.2019.0270 Rizzo, 2020, Recent advances of immunotherapy for biliary tract cancer, Expert Rev. Gastroenterol. Hepatol., 20 Valle, 2017, New horizons for precision medicine in biliary tract cancers, Cancer Discov., 7, 943, 10.1158/2159-8290.CD-17-0245 Sohal, 2016, Molecular characteristics of biliary tract cancer, Crit. Rev. Oncol. Hematol., 107, 111, 10.1016/j.critrevonc.2016.08.013 Rizzo, 2021, Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer, Expert Opin. Investig. Drugs, 1 Massa, 2020, Evolution of the experimental models of cholangiocarcinoma, Cancers Basel, 12, 2308, 10.3390/cancers12082308 Weinberg, 2019, Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets, J. Gastrointest. Oncol., 10, 652, 10.21037/jgo.2018.08.18 Ricci, 2020, Immunotherapy in biliary tract cancer: worthy of a second look, Cancer Control, 27, 10.1177/1073274820948047 Morizane, 2018, New developments in systemic therapy for advanced biliary tract cancer, Jpn. J. Clin. Oncol., 48, 703, 10.1093/jjco/hyy082 Ricci, 2020, The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box?, ESMO Open., 5, 10.1136/esmoopen-2020-001042 Chakrabarti, 2020, Targeted therapies in advanced biliary tract cancer: an evolving paradigm, Cancers Basel, 12, 2039, 10.3390/cancers12082039 Jusakul, 2017, Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma, Cancer Discov., 7, 1116, 10.1158/2159-8290.CD-17-0368 Nakamura, 2015, Genomic spectra of biliary tract cancer, Nat. Genet., 47, 1003, 10.1038/ng.3375 Athauda, 2020, Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation, Cancer Treat. Rev., 86, 10.1016/j.ctrv.2020.101998 Oneda, 2020, Biliary tract cancer: current medical treatment strategies, Cancers Basel, 12, 1237, 10.3390/cancers12051237 Javle, 2016, Biliary cancer: utility of next-generation sequencing for clinical management, Cancer., 122, 3838, 10.1002/cncr.30254 Zhao, 2017, Current biologics for treatment of biliary tract cancers, J. Gastrointest. Oncol., 10.21037/jgo.2017.05.04 Mahipal, 2018, Novel targeted treatment options for advanced cholangiocarcinoma, Expert Opin. Investig. Drugs, 27, 709, 10.1080/13543784.2018.1512581 Saborowski, 2020, FGFR inhibitors in cholangiocarcinoma: what's now and what's next?, Ther. Adv. Med. Oncol., 12, 10.1177/1758835920953293 Salati, 2020, IDH signalling pathway in cholangiocarcinoma: from biological rationale to therapeutic targeting, Cancers Basel, 12, 3310, 10.3390/cancers12113310 Chun, 2017, Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma, Cancer Control., 24, 10.1177/1073274817729241 Subbiah, 2020, Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial, Lancet Oncol., 21, 1234, 10.1016/S1470-2045(20)30321-1 Rizvi, 2017, Emerging molecular therapeutic targets for cholangiocarcinoma, J. Hepatol., 67, 632, 10.1016/j.jhep.2017.03.026 Jain, 2016, Molecular profiling of biliary tract cancer: a target rich disease, J. Gastrointest. Oncol., 7, 797, 10.21037/jgo.2016.09.01 Papadopoulou, 2018, Genotyping and mRNA profiling reveal actionable molecular targets in biliary tract cancers, Am. J. Cancer Res., 8, 2 Rizzo, 2021, Pemigatinib: hot topics behind the first approval of a targeted therapy in cholangiocarcinoma, Cancer Treat. Res. Commun., 27 Javle, 2019, Systemic therapy for gallbladder cancer, Chin. Clin. Oncol., 8, 44, 10.21037/cco.2019.08.14 Marks, 2016, Molecular genetics and targeted therapeutics in biliary tract carcinoma, World J. Gastroenterol., 22, 1335, 10.3748/wjg.v22.i4.1335 Mertens, 2018, Targeting cholangiocarcinoma, Biochim. Biophys. Acta Mol. Basis Dis., 1864, 1454, 10.1016/j.bbadis.2017.08.027 Lamarca, 2018, Biliary tract cancer: state of the art and potential role of DNA damage repair, Cancer Treat. Rev., 70, 168, 10.1016/j.ctrv.2018.09.002 Hoy, 2020, Pemigatinib: first approval, Drugs, 80, 923, 10.1007/s40265-020-01330-y Abou-Alfa, 2020, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Lancet Oncol., 21, 671, 10.1016/S1470-2045(20)30109-1 Rizzo, 2020, Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives, Expert Opin. Investig. Drugs, 25, 1 Mazzaferro, 2019, Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma, Br. J. Cancer, 120, 165, 10.1038/s41416-018-0334-0 Fostea, 2020, Recent Progress in the systemic treatment of advanced/metastatic cholangiocarcinoma, Cancers Basel, 12, 2599, 10.3390/cancers12092599 Rizzo, 2020, Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives, Cancer Genom. Proteom., 17, 441, 10.21873/cgp.20203 Goyal, 2019, TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma, Cancer Discov., 9, 1064, 10.1158/2159-8290.CD-19-0182 Rizzo, 2020, Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis, Ther. Adv. Med. Oncol., 12, 10.1177/1758835920936932 Personeni, 2020, Biliary tract cancers: molecular heterogeneity and new treatment options, Cancers Basel, 12, 3370, 10.3390/cancers12113370 Montalban-Bravo, 2018, The role of IDH mutations in acute myeloid leukemia, Future Oncol., 14, 979, 10.2217/fon-2017-0523 Waitkus, 2018, Biological role and therapeutic potential of IDH mutations in cancer, Cancer Cell, 34, 186, 10.1016/j.ccell.2018.04.011 Dang, 2016, IDH mutations in cancer and progress toward development of targeted therapeutics, Ann. Oncol., 27, 599, 10.1093/annonc/mdw013 Fujii, 2016, Targeting isocitrate dehydrogenase (IDH) in cancer, Discov. Med., 21, 373 Clark, 2016, Molecular pathways: isocitrate dehydrogenase mutations in cancer, Clin. Cancer Res., 22, 1837, 10.1158/1078-0432.CCR-13-1333 Liu, 2015, Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors, Histol. Histopathol., 30, 1155 Krell, 2013, IDH mutations in tumorigenesis and their potential role as novel therapeutic targets, Future Oncol., 9, 1923, 10.2217/fon.13.143 Gu, 2020, IDH1 mutation contributes to myeloid dysplasia in mice by disturbing heme biosynthesis and erythropoiesis, Blood Zhang, 2020, Systemic treatment of advanced or recurrent biliary tract cancer, Biosci. Trends, 14, 328, 10.5582/bst.2020.03240 Rizzo, 2020, Second-line treatment in advanced biliary tract cancer: today and tomorrow, Anticancer Res., 40, 3013, 10.21873/anticanres.14282 Ntanasis-Stathopoulos, 2020, Cholangiocarcinoma: investigations into pathway-targeted therapies, Expert Rev. Anticancer Ther., 20, 765, 10.1080/14737140.2020.1807333 Ludwig, 2017, Molecular markers in glioma, J. Neurooncol., 134, 505, 10.1007/s11060-017-2379-y Bose, 2017, Treatment of relapsed/refractory acute myeloid leukemia, Curr. Treat. Opt. Oncol., 18, 17, 10.1007/s11864-017-0456-2 Miller, 2017, Isocitrate dehydrogenase-mutant glioma: evolving clinical and therapeutic implications, Cancer, 123, 4535, 10.1002/cncr.31039 Farshidfar, 2017, Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles, Cell Rep., 18, 2780, 10.1016/j.celrep.2017.02.033 Lowery, 2019, Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study, Lancet Gastroenterol. Hepatol., 4, 711, 10.1016/S2468-1253(19)30189-X Abou-Alfa, 2020, Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol., 21, 796, 10.1016/S1470-2045(20)30157-1 Gervaso, 2020, Ivosidenib for advanced IDH1-mutant cholangiocarcinoma, Lancet Oncol., 21, e370, 10.1016/S1470-2045(20)30343-0 Zhu, 2021, Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation, J. Clin. Oncol., 39, 266, 10.1200/JCO.2021.39.3_suppl.266 Saha, 2016, Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma, Cancer Discov., 6, 727, 10.1158/2159-8290.CD-15-1442 Sulkowski, 2017, 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity, Sci. Transl. Med., 9, eaal2463, 10.1126/scitranslmed.aal2463 Jin, 2011, 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations, PLoS ONE, 6, e16812, 10.1371/journal.pone.0016812 Sharma, 2018, Development of novel therapeutics targeting isocitrate dehydrogenase mutations in cancer, Curr. Top. Med. Chem., 18, 505, 10.2174/1568026618666180518091144 Schvartzman, 2019, 2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation, Proc. Natl. Acad. Sci. U.S.A., 116, 12851, 10.1073/pnas.1817662116